Introduction Zeposia is the brand name of ozanimod, an oral immunomodulatory drug used mainly in relapsing forms of multiple sclerosis and moderately to severely active ulcerative colitis. It belongs to the class of sphingosine-1-phosphate receptor modulators, commonly called S1P receptor modulators. Zeposia is important in pharmacology because it does not act like a conventional anti-inflammatory … Read more
Introduction Vedolizumab is a humanized IgG1 monoclonal antibody used for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. It selectively targets the gastrointestinal immune system, offering gut-specific immunomodulation with minimal systemic immunosuppression. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Bioavailability Not applicable (IV administration) Half-life ~25.5 days Volume … Read more
Introduction Entyvio (vedolizumab) is a recombinant humanized IgG1 monoclonal antibody that targets the α4β7 integrin on gut-homing T-lymphocytes. It is approved for moderate to severe ulcerative colitis and Crohn’s disease, particularly in patients who have not responded to or cannot tolerate TNF antagonists. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion (300 mg) … Read more
Introduction Tofacitinib is an oral Janus kinase (JAK) inhibitor, primarily targeting JAK1 and JAK3. It blocks intracellular signaling of multiple inflammatory cytokines and is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and other immune-mediated diseases. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral Bioavailability ~74% Time to Peak (Tmax) … Read more
Introduction Stelara (ustekinumab) is a fully human IgG1κ monoclonal antibody designed to target key cytokines involved in immune-mediated diseases. It selectively binds to the p40 subunit common to interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors. Stelara is approved for several chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, … Read more
